Search Results

While rare, health care costs associated with these conditions are long term and can be devastating. MS is the most common autoimmune disorder of the CNS, and worldwide, ~2.3 million people are affected Most people experience their first symptoms of MS between the ages of 20 and 40. Currently there is no cure for MS and many medications have serious side effects and some carry significant (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics

Management of symptoms is done through a multidisciplinary approach utilizing medication for motor difficulties (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

Conference Call / Webcast Information: The live webcast of the conference call can be accessed online at https (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most and Biology Volume 964 (2017) Sigma Receptors: Their Role in Disease and as Therapeutic Targets. [2] https

rapid advancements in Alzheimer’s disease diagnostics and therapeutics that make this field one of the most dynamic in medical research today. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most

Webcast Information: A live webcast of the presentation will be available on http://www.veracast.com/ (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

"There is a substantial unmet medical need for a drug that can effectively address all symptoms of schizophrenia (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most

“There is a tremendous unmet medical need around the globe caused by Alzheimer’s disease. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most

Additional information about the conference is available at http://www.alz.org/icad/overview.asp . About Alzheimer’s Disease While Alzheimer’s disease is most common in people over the age of 65, it can Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1

Conference Call / Webcast Information Anavex will host a conference call and webcast today at 4:30 p.m The live webcast of the conference call may be accessed online at http://www.wsw.com/webcast/cc/avxl12 (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

“We are pleased with the rigorous and efficient execution of the confirmatory late-stage Precision Medicine Webcast / Conference Call Information: The live webcast of the conference call can be accessed online at https (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most

Management will host a conference call on Wednesday, December 12, 2018. at 4:30pm Eastern Time to review Conference Call / Webcast Information: The live webcast of the conference call can be accessed online at http (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

Management will host a conference call on Thursday February 7, 2019 at 4:30pm Eastern Time to review Conference Call / Webcast Information: The live webcast of the conference call can be accessed online at http (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: